双特异性抗体在非小细胞肺癌治疗中的进展

Progress of bispecific antibody in the treatment of non-small cell lung cancer

双特异性抗体(BsAb)是一种可以同时或先后特异性结合两个抗原或抗原表位的新型高效抗肿瘤药物。目前,靶向表皮生长因子受体(EGFR)和cMET的埃万妥珠单抗已获批应用于治疗EGFR ex20ins的局部晚期或转移性非小细胞肺癌(NSCLC),靶向程序性死亡蛋白配体-1(PD-L1)和细胞毒性T淋巴细胞相关抗原-4(CTLA-4)、程序性死亡蛋白-1(PD-1)和CTLA-4、PD-L1和转化生长因子-β、PD-1和血管内皮生长因子的抑制剂应用于NSCLC的治疗正在进行中,均表现出良好的安全性和有效性。深入探讨BsAb在NSCLC治疗中的研究进展,将为临床治疗NSCLC提供新的诊疗思路。

Bispecific antibody(BsAb)is a new type of highly effective anti-tumor drug that can specifically bind two antigens or epitopes simultaneously or successively.At present,evantuzumab targeting epidermal growth factor receptor(EGFR)and cMET has been approved for the treatment of EGFR ex20ins in locally advanced or metastatic non-small cell lung cancer(NSCLC).Inhibitors targeting programmed deathligand 1(PD-L1)and cytotoxic T lymphocyte antigen-4(CTLA-4),programmed death-1(PD-1)and CTLA-4,PD-L1 and transforming growth factor-β,PD-1 and vascular endothelial growth factor are applied to NSCLC.The treatment of NSCLC is underway,showing good safety and efficacy.Further exploring the research progress of BsAbs in the treatment of NSCLC will provide a new diagnosis and treatment idea for the clinical treatment of NSCLC.